Weidong Yin

Sinovac Biotech — China

Medicine · Health Sciences

24h-index6.7kcitations48works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(21), Viral gastroenteritis research and epidemiology(13), Viral Infections and Immunology Research(12), Influenza Virus Research Studies(11), COVID-19 Clinical Research Studies(9)

Publications48 total

Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study
Emerging Microbes & Infections·2023· 18 citedOpen Access
Post-Exposure Prophylaxis with SA58 (anti-COVID-19 monoclonal antibody) Nasal Spray for the prevention of symptomatic Coronavirus Disease 2019 in healthy adult workers: A randomized, single-blind, placebo-controlled clinical study
2023· 2 citedOpen Access
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
Cell Reports·2022· 152 citedOpen Access
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
2022· 13 citedOpen Access
Safety profile of COVID-19 vaccines in pregnant and postpartum women in brazil
2021· 3 citedOpen Access
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
The Lancet Infectious Diseases·2021· 284 citedOpen Access
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
2021· 37 citedOpen Access
Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial
2021· 74 citedOpen Access
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
The Lancet Infectious Diseases·2021· 572 citedOpen Access
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
The Lancet Infectious Diseases·2020· 1.5k citedOpen Access
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
2020· 95 citedOpen Access
Development of an inactivated vaccine candidate for SARS-CoV-2
Science·2020· 1.5k citedOpen Access
Rapid development of an inactivated vaccine for SARS-CoV-2
2020· 77 citedOpen Access
Immunogenicity and Safety of a Sabin Strain–Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial
The Journal of Infectious Diseases·2019· 34 citedOpen Access
The hUC-MSCs cell line CCRC-1 represents a novel, safe and high-yielding HDCs for the production of human viral vaccines
Scientific Reports·2017· 14 citedOpen Access
Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.
PubMed·2017· 7 cited
Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013–2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®
Human Vaccines & Immunotherapeutics·2016· 6 citedOpen Access
Hepatitis A virus and the origins of picornaviruses
Nature·2014· 194 cited
Establishment of a novel triple-transgenic mouse: conditionally and liver-specifically expressing hepatitis C virus NS3/4A protease
Molecular Biology Reports·2014· 2 cited
Human diploid MRC-5 cells exhibit several critical properties of human umbilical cord-derived mesenchymal stem cells
Vaccine·2014· 49 cited
page 1 of 3Next →

Frequent Co-authors

Junzhi Wang(10), Qiang Gao(9), Yaling Hu(7), Changgui Li(7), Xiangxi Wang(7), Chuan Qin(7), Fengcai Zhu(7), Jiang-Ting Chen(7), Gang Zeng(6), Deyu Jiang(5), Xuejie Gong(5), Kai Chu(5), Qiang Gao(5), Linlin Bao(4), Minnan Yang(4), Hong Gao(4), Biao Kan(4), Yanjun Zhang(4), Hongxing Pan(4), Yuansheng Hu(4)